GLP-1 TV · Patient story · views checked Oct 2026
Eli Lilly's New GLP-1 pill Orforglipron (Foundayo) Explained | Why it's NOT just oral Zepbound
Our summary
A patient explains how Wegovy works and what the evidence says, mentioning 17.2 mg. Also covers injection technique and the trials.
One person's experience, in their words. Not medical advice.
Key moments
From the creator's own chapters. Tap one to play from there.
- 0:00 A new weight loss pill that could shake things up
- 0:32 Why this matters if you’re comparing GLP-1 options
- 0:53 What Orforglipron is
- 1:33 Why Orforglipron is different from peptide GLP-1 drugs
- 3:21 Why the pill format may be easier for many people
- 3:49 Oral semaglutide comparison and dosing convenience
- 5:06 Who Orforglipron may be for
- 6:36 Trial results and expected weight loss
What the video says
As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.
- Medication
- Wegovy, Zepbound, Mounjaro and Foundayo
- Doses mentioned
- 17.2 mg
- Who is speaking
- Patient
Find more like it
Side effectsDose changeWeigh-in and resultsInjection techniqueHow it worksThe trials
Up next
More from this collection
Watched it? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.




















